Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Crofelemer

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 7,823Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Jaguar Health Announces Abstract Submission for Preliminary Data
    Jaguar Health Announces Abstract Submission for Preliminary Data

    15 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-15/jaguar-health-announces-abstract-submission-for-preliminary-data-from-us-investigator-initiated-tria

    PHARMIWEB
    15 Dec 2025
    Share Share
    FDA Renews Canalevia-CA1 Approval for Chemo Diarrhea
    FDA Renews Canalevia-CA1 Approval for Chemo Diarrhea

    10 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-10/fda-approves-renewal-of-canalevia-ca1-jaguar-healths-drug-for-chemotherapy-induced-diarrhea-cid

    PHARMIWEB
    10 Dec 2025
    Share Share
    Jaguar Health Approves All Proposals at December 2025 Meeting
    Jaguar Health Approves All Proposals at December 2025 Meeting

    08 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-08/jaguar-health-reports-approval-of-all-proposals-at-december-2025-special-meeting-of-stockholders

    PHARMIWEB
    08 Dec 2025
    Share Share
    Jaguar Health Files EMA Application for Canalevia in Dogs
    Jaguar Health Files EMA Application for Canalevia in Dogs

    02 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-02/jaguar-health-makes-submission-to-ema-regarding-eu-approval-pathway-for-canalevia-for-general-diarrh

    PHARMIWEB
    02 Dec 2025
    Share Share
    Jaguar Health Strengthens Global IP With New Crofelemer Patent
    Jaguar Health Strengthens Global IP With New Crofelemer Patent

    24 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-24/jaguar-health-secures-new-patent-for-crofelemer-in-short-bowel-syndrome-strengthening-global-ip-pos

    PHARMIWEB
    24 Nov 2025
    Share Share
    Jaguar Health Submits Amended Protocol To FDA For Crofelemer
    Jaguar Health Submits Amended Protocol To FDA For Crofelemer

    20 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-20/in-support-of-possible-expedited-approval-pathway-for-crofelemer-for-treatment-of-microvillus-inclus

    PHARMIWEB
    20 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.